Selank Dosaging Guide
Research Disclaimer Content on this page is for research and educational purposes only. BioLabDirect products are sold as research chemicals and are not for human or veterinary use, diagnosis, treatment, or disease prevention. Nothing here is medical advice, a dosing protocol, or a clinical claim. Always follow institutional lab policies and applicable regulations.
For Research Purposes Only.
This Selank dosaging guide is a laboratory reference covering what the literature says Selank is, how to calculate stock concentration from a 5 mg vial, practical storage notes, and how to verify a lot on its Certificate of Analysis. It does not provide instructions for use in people or animals and makes no medical claims. Browse the research peptide catalog for other materials.
Internal resources:
- Selank research peptide (5mg vial)
- Peptide reconstitution calculator
- COA library (third-party lab reports)
- CJC-1295 No DAC Dosaging Guide · TB-500 Dosaging Guide
- Related research peptides: Semax · CJC-1295 No DAC
Selank in a Research Context
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, described in the literature as an analog of the peptide tuftsin (Kolomin et al., 2011; Kolomin et al., 2014). It is supplied for research as a lyophilized powder.
| Item | Detail for lab planning |
|---|---|
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Form supplied | Lyophilized powder, 5 mg vial |
| Identity and purity | Verify on the lot CoA (mass spectrometry and HPLC) |
Experimental Themes in the Published Literature
- Gene-expression profiling, mouse spleen: Kolomin et al. (2011) analyzed 84 inflammation-related genes after a single administration and reported expression changes in 34 of them; Kolomin et al. (2014) followed the time course of four genes (C3, Casp1, Il2rg, Xcr1).
- Gene-expression profiling, rat hippocampus: Kolomin et al. (2013) used cDNA microarrays and reported that mRNA levels of 36 genes changed more than two-fold after a single administration (English abstract only).
- In vitro enzyme assay: Kost et al. (2001) reported dose-dependent inhibition of enkephalin-degrading enzymes from human serum by Selank and Semax, with an IC50 of about 20 µM for Selank (English abstract only).
These are descriptions of findings in specific models and assays, not statements about any BioLabDirect product.
Reconstitution and Concentration Math for Laboratory Research
To prepare a 5 mg vial for assay work, divide the labelled mass by the diluent volume to get the stock concentration, then divide your target mass by that concentration to get the volume to draw. Keep units consistent (1 mg = 1,000 µg) and use the CoA net peptide content if given. The peptide reconstitution calculator does this for you.
| Step | Calculation | Result |
|---|---|---|
| 1. Vial content | Label amount | 5 mg of Selank |
| 2. Diluent added | Chosen by the lab for the assay | 2 mL |
| 3. Stock concentration | 5 mg ÷ 2 mL | 2.5 mg/mL (2,500 µg/mL) |
| 4. Example working aliquot | 250 µg ÷ 2,500 µg/mL | 0.1 mL (100 µL) |
The 250 µg target is a neutral arithmetic illustration and is not drawn from any study. Changing the diluent volume changes concentration proportionally, so log the volume used.
Amounts Reported in Preclinical Studies
This guide deliberately does not restate administration amounts from animal studies. In the cited papers, amounts are expressed in species-specific units and tied to route, vehicle and endpoint, which makes them unsuitable to copy between experiments. Please read the methods sections of the primary papers (Kolomin et al., 2011, 2013, 2014) for exact parameters. The one in vitro figure quoted here, an IC50 of about 20 µM against enkephalin-degrading enzymes in human serum, comes from Kost et al. (2001). Use the calculator to convert any target of your own into volumes.
Storage and Handling for a 5 mg Selank Vial
- Keep unopened vials as the lot CoA directs; avoid warming and light exposure.
- At 2.5 mg/mL, a 100 µL aliquot holds 250 µg, so a 2 mL stock yields 20 such aliquots.
- The Selank sequence contains no cysteine or methionine residues, which removes two common oxidation concerns; solution stability still depends on pH, temperature and buffer, so confirm it in your own system (Manning et al., 2010, review general principles).
- Label tubes with date, concentration and diluent.
Reading the Selank CoA
For a seven-residue peptide, mass and purity are straightforward to read:
- the lot number on the vial matches the report;
- the observed mass is consistent with the Thr-Lys-Pro-Arg-Pro-Gly-Pro sequence;
- HPLC purity, test date and testing laboratory are stated.
Find reports in the COA library.
Frequently Asked Questions
What is Selank?
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) described in the literature as a tuftsin analog, supplied as a lyophilized powder for laboratory research.
How do I calculate stock concentration for a 5 mg vial?
Divide mass by diluent volume: 5 mg in 2 mL is 2.5 mg/mL (2,500 µg/mL). Other volumes are covered by the calculator. This is laboratory arithmetic only.
Where can I find the parameters used in published Selank studies?
In the methods sections of the primary papers listed in the references. This guide does not restate animal-study amounts, and nothing here is guidance for use in people or animals.
What does the in vitro IC50 in this guide refer to?
Kost et al. (2001) measured inhibition of enkephalin-degrading enzymes from human serum in vitro; the reported IC50 for Selank was about 20 µM.
How should I verify my Selank lot?
Match the lot number to the COA library report and check that the observed mass fits the heptapeptide sequence.
References
Please read each full paper before relying on any detail.
- Kolomin T, Shadrina M, Andreeva L, Slominsky P, Limborska S, Myasoedov N. Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank. Regul Pept. 2011;170(1-3):18–23. PMID: 21609736. DOI: 10.1016/j.regpep.2011.05.001.
- Kolomin T, Morozova M, Volkova A, et al. The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. Mol Immunol. 2014;58(1):50–55. PMID: 24291245. DOI: 10.1016/j.molimm.2013.11.002.
- Kolomin TA, Agapova TIu, Agniullin IaV, et al. Transcriptome alteration in hippocampus under the treatment of tuftsin analog Selank [in Russian; English abstract]. Zh Vyssh Nerv Deiat Im I P Pavlova. 2013;63(3):365–374. PMID: 24450168. DOI: 10.7868/s0044467713030052.
- Kost NV, Sokolov OIu, Gabaeva MV, et al. Semax and selank inhibit the enkephalin-degrading enzymes from human serum [in Russian; English abstract]. Bioorg Khim. 2001;27(3):180–183. PMID: 11443939. DOI: 10.1023/a:1011373002885.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. PMID: 20143256. DOI: 10.1007/s11095-009-0045-6.
Research Disclaimer This article is educational only. BioLabDirect sells research chemicals not intended for human consumption or clinical use. No statement here establishes safety or effectiveness for any condition, and nothing here is a recommendation for any person or animal. Follow institutional biosafety rules.
For Research Purposes Only.
